Backgrond An impaired coronary flow reserve in syndrome X has been demonstrated by many studies. Recently, however, a normal coronary flow reserve in response to papaverine was reported, but the number of patients in these studies was small. The aim of this study was to investigate whether coronary flow reserve in response to intracoronary papaverine is really impaired in syndrome X.
Key Words * syndrome X * coronary flow reserve d papaverine T he spectrum of current controversy regarding the pathophysiology of syndrome X is wide and seems to include all aspects of the disease.1 Until recently, it was thought that an impaired coronary flow reserve was the one finding that could be demonstrated in a substantial proportion of patients with syndrome X, and its presence was used as the strongest argument in favor of the ischemic nature of this syndrome.1 Recently, however, there have been reports of a normal vasodilator response to intracoronary papaverine in patients with syndrome X.2,3 In both of these studies, coronary flow response to intracoronary papaverine was measured with an intracoronary Doppler catheter, and the results suggested that coronary flow reserve is normal in syndrome X patients. However, the number of patients in these studies was small. This study was performed to see whether these observations could be substantiated in a larger number of syndrome X patients. Methods
Coronary flow reserve in response to intracoronary papaverine was measured in 53 patients with syndrome X and in 26 heart transplant patients with completely normal coronary arteries (control group).
Syndrome X Group Fifty-three syndrome X patients were studied, 22 men and 31 women. All patients gave a history of chest pain typical of angina pectoris. There was no evidence of cardiovascular disease on physical examination. The exercise ECG was positive in every patient. The Bruce protocol was used for the exercise test, and the test was said to be positive if there was at least 1 mm of horizontal or downward-sloping ST segment depression at 80 milliseconds after the J-point. The left ventricle and the coronary arteries were completely normal on angiography, as confirmed by two independent observers; if there was no consensus between the two observers, patients were excluded. All patients had to have completely smooth coronary arteries on angiography; patients with even minor irregularities were excluded from the study. Patients with hypertension, diabetes mellitus, and valvular heart disease or left ventricular hypertrophy were excluded from the study. All patients had continued to have chest pain despite reassurances after their initial cardiac catheterization and were taking antianginal medications.
Transplant Group
Twenty-six heart transplant patients were studied, 22 men and 4 women. All patients were more than 1 year after their heart transplant operation. None of these patients had chest pain. There were no ischemic changes on exercise testing in these patients. Coronary flow reserve studies were performed at the time of their routine follow-up cardiac catheterization. Currently, we follow our transplant patients annually with repeat coronary angiography for the detection of coronary occlusive disease. In all patients, the coronary angiograms were reviewed before the study by two independent observers, and only patients with completely normal coronary arteries were included in the study. where r is the coronary artery radius as determined by quantitative analysis of the angiograms obtained in the preselected views. To obtain an estimate of coronary blood flow at rest (in millimeters per minute), the resting cross-sectional area of the coronary artery (in square centimeters) was multiplied by the mean coronary blood flow velocity (in centimeters per second) and by 60 seconds.
Statistical Analysis
Values are given as mean±SD. Unpaired t tests were used for comparison of group means. Paired t tests were used to compare the arterial diameter measurements before and after the hyperemic dose of papaverine. Differences were considered to be statistically significant at the P<.05 level.
Results
The patient variables are shown in 23 to 56 years). The mean duration after the heart transplant was 42±19 months. There was no significant difference in the left ventricular ejection fractions between the two groups.
Echocardiographic Measurements
The echocardiographic measurements are presented in Table 2 . There were no significant differences between the two groups.
Exercise Test Data
The exercise test data are presented in Table 3 . The transplant group had a significantly higher resting heart rate and systolic pressure than the syndrome X group. All the syndrome X patients developed their typical anginal chest pain during the exercise test, and the exercise test was positive in all patients as defined earlier.
The maximum ST-segment depression in the syndrome X group was 1.84±0.63 mm. The exercise test was discontinued in all transplant patients because of fatigue, and none of the patients developed chest pain. There were no significant ECG changes on exercise in any of the transplant group. The peak heart rate re- The mean values for the measurements of coronary flow velocity and coronary flow reserve are shown in Table 4 . There was no significant change in the heart rate or mean arterial pressure on injection of the hyperemic dose of intracoronary papaverine. The coronary flow velocity at rest was not significantly different between the two groups. The coronary flow reserve was significantly lower in the syndrome X group (2.72+1.39) compared with the transplant group (5.22±1.26; P<.01; Figure) .
Quantitative Measurements
There was no significant difference in the resting diameter of the left anterior descending coronary artery in the region of the Doppler catheter between the syndrome X group (3.87±0.21 mm) and the transplant group (3.92±0.11, P=NS). There was no significant difference in estimated coronary blood flow at rest (coronary blood flow velocity corrected for changes in coronary cross-sectional area) between the syndrome X and transplant groups (63±33 versus 54±28 mLmin, P=NS). The left anterior descending coronary artery diameter also did not change significantly at peak hyperemia after papaverine in both the syndrome X (3.91±0.20 mm, P=NS) and the transplant (3.98±0.15 mm, P=NS) groups. The mean percentage change at peak hyperemia in the luminal diameter of the left anterior descending coronary artery was 4.0±6.0% in the syndrome X group and 1.6±2.4% in the transplant group. The In our study, a much larger number of syndrome X patients were studied, and patients were included only after strict selection criteria had been satisfied. The response of heart transplant patients to intracoronary papaverine was reported previously.15 The coronary flow results in the transplant group in our study are in keeping with normal coronary flow reserve values reported previously.14'15 The heart transplant group in our study provides a "normal" control group. All the transplant patients had completely normal coronary arteries, and the normal response to papaverine seen in this study reflects this. The presence of even minor coronary occlusive disease causes an impairment in coronary flow reserve in orthotopic heart transplants.7 In the absence of an ideal control group of normal healthy volunteers, the transplant group in this study probably provides the best alternative comparison.
It may be argued that hearts with normal innervation show basal a-mediated vasoconstrictor tone that limits coronary flow reserve and that, therefore, the heart transplant subjects are simply not true normal control subjects. However, the subject of resting adrenergic tone in humans is controversial. The presence or absence of resting adrenergic tone in the coronary vasculature has been the subject of much investigation. Conflicting results have been found by previous studies in unstressed conscious animals and humans. Whereas some studies demonstrated significant decreases in vascular resistance after a-blockade,'8-2' others were unable to demonstrate any change.22'23 Significant a-adrenergic coronary constrictor tone at rest has been suggested by studies in anesthetized24 and conscious dogs.25 '26 In contrast, Chilian et al,22 in well-controlled experiments, were unable to demonstrate any a-adrenergic coronary constrictor tone in conscious dogs. Some evidence for resting a-adrenergic coronary constrictor tone in humans was provided by the observation that normally innervated patients are characterized by a higher resting coronary resistance and a higher coronary arteriovenous oxygen difference than cardiac transplant patients, the difference being abolished by nonselective a-blockade with phentolamine.18 However, the conclusions of this study are based largely on the use of coronary sinus thermodilution, which is not suitable to detect small changes in coronary blood flow. [mean±SD] from transplant to study) and 19 normally innervated patients with angiographically normal coronary arteries. Coronary blood flow velocity was measured with a subselective intracoronary Doppler catheter, and coronary flow reserve was assessed by intracoronary papaverine. Regional a-blockade was produced by intracoronary injection of the nonselective a-blocker phentolamine. The mean coronary flow velocity decreased significantly in both groups of patients, but this was associated with a significant reduction in mean arterial pressure. However, there was no change in the calculated coronary vascular resistance, which takes the changes in arterial pressures into account.
Coronary flow reserve also did not change in either patient group after a-blockade, suggesting that a-receptor-mediated vascular tone is negligible in both denervated transplant patients and normally innervated subjects. Indolfi et a129 also recently showed that regional infusion of an a2-adrenergic receptor blocking agent (yohimbine) does not change resting coronary blood flow in normal coronary arteries, suggesting that resting a2-adrenergic vasoconstriction does not exist in humans.
To avoid the effects of f-adrenergic-stimulation on regional coronary blood flow, their study was performed in the presence of P-blockade.
The mean Doppler coronary flow velocity at rest in our study was not significantly different in the syndrome X and transplant groups. This is in contrast to studies using positron emission tomography that have indicated that resting coronary flow is increased in patients with syndrome X, suggesting that the reduction in flow reserve in syndrome X is related to an increase in resting myocardial perfusion as opposed to the maximal perfusion available during stress.31b3' In the study by Galassi et al,30 the baseline myocardial blood flow was greater in the syndrome X group than in healthy subjects and was more heterogeneous (as assessed by the coefficient of variation among myocardial regions <2.3 cm3). Myocardial blood flow after dipyridamole, however, was similar to that in the healthy subjects, although it was still more heterogeneous than in the healthy subjects. Geltman et a131 also demonstrated grater baseline myocardial blood flow in patients with angina and normal coronary arteries than in healthy subjects, but in contrast to the study by Galassi et al, the mean blood flow after dipyridamole and the myocardial perfusion reserve were significantly lower in patients with chest pain and normal coronary arteries than in the healthy subjects. Geltman et al, using larger tissue regions of interest, also reported that myocardial perfusion was homogeneous in normal subjects and patients at rest and after dipyridamole. It is notable that the resting myocardial blood flow of the control subjects in the study by Geltman et al was higher than that in the study by Galassi et al (1.25 3 Holdright et al estimated coronary blood flow before and after intracoronary bolus injections of 8 mg of papaverine. It was shown previously that many patients do not achieve maximal coronary vasodilation in the left coronary artery until at least 12 mg is administered. 16 The observations in the present study also confirm this. Therefore, there is also the possibility that in the study by Holdright et al, some patients did not achieve maximal vasodilation.
The mechanism of action of papaverine is not dependent on the endothelium or adenosine production. The reduced flow response to papaverine in the syndrome X group seems to exclude the possibility that impaired flow responses could be related to an abnormal endothelium-dependent function or adenosine responsiveness. The results of our study suggest that the abnormalities in flow reserve in syndrome X are related to either a structural abnormality in the microcirculation or a functional abnormality in smooth muscle relaxation that affects both adenosine-and papaverine-mediated vasodilation. However, the presence of an impaired endothelium-dependent vasodilation in syndrome X patients has also been reported previously.38 It is clear from our study that a number of syndrome X patients have a normal flow response to papaverine, and the possibility that some of these patients may have an impaired endothelium-dependent vasodilation cannot be ruled out.
It is now generally believed that syndrome X almost certainly encompasses several pathophysiological disease entities. Coronary flow reserve studies have demonstrated an impaired flow response to pacing stress and to pharmacological vasodilatation. The fact that these abnormalities have been demonstrated by several different methodologies further strengthens the conclusion that an abnormal flow reserve does exist. However, it is also clear that other patients with chest pain and normal coronary arteries do not have any evidence of an abnormal coronary flow reserve, suggesting that syndrome X, even if defined by the ECG response to exercise, probably consists of more than one distinct pathophysiological entity. Therefore, it would be unreasonable to ascribe the angina in all syndrome X patients to an impaired flow reserve. This suggests that other factors must also be important. An abnormal pain perception,39 a significant reduction in coronary blood flow on esophageal acid stimulation,40 a significant reduction in coronary blood flow on hyperventilation with and without epicardial coronary constriction,8,41 a heightened sympathetic tone,42 insulin resistance,43v" and an abnormal microvascular endothelial dysfunction38 have all been reported in syndrome X; these findings highlight the heterogeneous nature of this syndrome.
Limitations of the Study
We recognize that the use of heart transplant patients as "normal" control subjects is far from ideal. However, they probably provide the best alternative given the ethical considerations involved in studying completely normal individuals.
There is now evidence that spontaneous reinnervation of the transplanted heart does occur.45 However, we did not study the transplant patients for the presence of sensory innervation. It is theoretically possible that sympathetic denervation may affect the responses of the coronary arteries to pharmacological stimuli.
Conclusions
The findings of this study have shown that the coronary flow reserve in response to papaverine is impaired in syndrome X patients, and they support the concept of microvascular dysfunction in a significant number of these patients. The results suggest that the abnormalities of flow reserve in syndrome X are related to either a structural abnormality in the microcirculation or a functional abnormality in smooth muscle relaxation.
